

HR 6710

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Feb 11, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Feb 14, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/6710>

Sponsor

Name: Rep. Herrell, Yvette [R-NM-2]

Party: Republican • **State:** NM • **Chamber:** House

Cosponsors (20 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Banks, Jim [R-IN-3]	R · IN		Feb 11, 2022
Rep. Cammack, Kat [R-FL-3]	R · FL		Feb 11, 2022
Rep. Cawthorn, Madison [R-NC-11]	R · NC		Feb 11, 2022
Rep. Donalds, Byron [R-FL-19]	R · FL		Feb 11, 2022
Rep. Gohmert, Louie [R-TX-1]	R · TX		Feb 11, 2022
Rep. Hern, Kevin [R-OK-1]	R · OK		Feb 11, 2022
Rep. Higgins, Clay [R-LA-3]	R · LA		Feb 11, 2022
Rep. Hudson, Richard [R-NC-8]	R · NC		Feb 11, 2022
Rep. Keller, Fred [R-PA-12]	R · PA		Feb 11, 2022
Rep. LaTurner, Jake [R-KS-2]	R · KS		Feb 11, 2022
Rep. McKinley, David B. [R-WV-1]	R · WV		Feb 11, 2022
Rep. Miller, Mary E. [R-IL-15]	R · IL		Feb 11, 2022
Rep. Miller-Meeks, Mariannette [R-IA-2]	R · IA		Feb 11, 2022
Rep. Norman, Ralph [R-SC-5]	R · SC		Feb 11, 2022
Rep. Scott, Austin [R-GA-8]	R · GA		Feb 11, 2022
Rep. Mann, Tracey [R-KS-1]	R · KS		Feb 15, 2022
Rep. Babin, Brian [R-TX-36]	R · TX		Feb 18, 2022
Rep. Hartzler, Vicky [R-MO-4]	R · MO		Feb 22, 2022
Rep. Jackson, Ronny [R-TX-13]	R · TX		Mar 7, 2022
Rep. Mooney, Alexander X. [R-WV-2]	R · WV		Mar 24, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 14, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 4792	Related bill	Sep 3, 2021: Referred to the Subcommittee on Energy and Mineral Resources.

Summary (as of Feb 11, 2022)

This bill requires the Food and Drug Administration (FDA) to report to Congress on barriers to the domestic manufacturing of imported active pharmaceutical ingredients, finished drug products, and devices that are critical to public health.

The report must recommend strategies to overcome such barriers. The FDA may, to the extent appropriate, implement the strategies.

Actions Timeline

- **Feb 14, 2022:** Referred to the Subcommittee on Health.
- **Feb 11, 2022:** Introduced in House
- **Feb 11, 2022:** Referred to the House Committee on Energy and Commerce.